Celator Pharmaceuticals Inc. (CPXX) Soared To A New High On Phase 3 News

Celator Pharmaceuticals Inc. (CPXX) announced after the bell Monday that its Phase 3 trial of VYXEOS Liposome for Injection met its primary endpoint, demonstrating a statistically significant improvement in overall survival in patients with high-risk acute myeloid leukemia.

from RTT - Before the Bell http://ift.tt/1UyEmQ6
via IFTTT